ArticleEndocrine connections2026
Tissue-specific HGF and soluble c-MET levels in gestational diabetes mellitus: insights into maternal-endocrine crosstalk and fetal metabolic adaptation.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hepatocyte growth factor (HGF)/c-MET signaling regulates glucose metabolism and tissue remodeling, but its role in gestational diabetes mellitus (GDM) remains unclear. We aimed to investigate maternal serum HGF and soluble c-MET (sc-MET) levels, their tissue expression in placenta and maternal visceral adipose tissue, and their associations with obstetric and perinatal outcomes in GDM. Methods: In this retrospective observational, cross-sectional study, 76 pregnant women (32 GDM, 44 normal glucose tolerance) were enrolled. Serum HGF and sc-MET were measured by ELISA; placental and visceral-fat HGF/c-MET expression was analyzed by RT-PCR and western blot. Clinical variables, including umbilical-cord blood gas and glucose values, were evaluated. Results: Maternal sc-MET levels were significantly higher, and cord-blood HGF levels significantly lower, in the GDM group. HGF protein expression was increased in maternal visceral fat but unchanged in placenta. Maternal HGF correlated negatively with cord base excess and positively with lactic acid levels, while cord HGF correlated positively with neonatal glucose. Conclusions: These findings indicate tissue-specific dysregulation of HGF/c-MET signaling in GDM, potentially linking maternal insulin resistance with fetal metabolic stress through visceral-fat-derived HGF. The associations between maternal HGF and neonatal lactic acid levels suggest an endocrine interaction influencing fetal adaptation. Further studies are needed to clarify underlying mechanisms across heterogeneous GDM phenotypes. Plain language summary: GDM is a condition that develops during pregnancy and affects how the body regulates sugar. This study explored how two proteins, HGF and its receptor c-MET, may influence metabolism in mothers with GDM and their babies. Blood, placenta, and visceral fat samples were analyzed from women with and without GDM. Mothers with GDM had higher blood levels of soluble c-MET and lower HGF levels in cord blood. HGF activity was increased in visceral fat, suggesting altered fat metabolism may contribute to insulin resistance. These changes were linked to higher lactic acid levels in newborns, a sign of metabolic stress. The findings suggest that HGF/c-MET signaling helps coordinate hormonal communication between mother and fetus during pregnancy and could serve as a potential biomarker for maternal insulin resistance and fetal metabolic health in GDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.